ZICCUM AB (publ) Interim report Q1 2022


To read the digital Report click here: https://reports-en.ziccum.com/interim-report-q1-2022/

Q1 2022

  • The result for the quarter amounted to -6,285 kSEK (-4, 416 kSEK)
  • Cash flow for the quarter amounted to 31,961 kSEK (-4, 818 kSEK)
  • Cash and cash equivalents at the end of the quarter amounted to 44, 234 kSEK (28,802 kSEK)
SUMMARY FINANCIAL HIGHLIGHTS kSEK Jan-March 2022 Jan-March 2021 Jan-Dec 2021
Net revenue                    –                    –                    –  
Operating result             (6,340)           (4,387)         (21,117)
Result             (6,285)           (4,416)         (21,136)
Balance sheet total            58,295          35,715          39,591
Cash flow            31,961           (4,818)         (21,347)
Cashy and cash equivalents            44,234          28,802          12,273
Equity ratio % 0.88 0.90 0.75
Data per share SEK
Number of shares at end of period     13,806,142      9,606,200      11,006,056
Result per share before and after dilution* -0.46              -0.46    -2.17
Cash flow per share 2.41              -0.50    -2.19
Equity per sharee 3.73                3.33    2.70
* Dilution effects is not calculated when the result is negative

Significant events during Q1 (Jan-March)
At the Extraordinary General Meeting held on January 18, in addition to approving the Board's proposal, it was decided to increase the limit on the number of shares and the size of the share capital in the Articles of Association, to enable the issue of the remaining 933,362 units in the private placement.

On January 18, an additional 2,800,086 shares and 1,866,724 warrants were registered, and all shares and warrants in the private placement are thus registered.

The last payments from the directed share issue were received by the company in January and February 2022, a total of 40 mSEK was added to the company after deduction of issue costs.

Ziccum announced on February 7 that it has become a member of the United Nations Global Compact, the world's largest corporate sustainability initiative.

On February 22, it was announced that Göran Conradson was terminated from his position as CEO. The company's CFO, Frida Hjelmberg, will be acting CEO for the time being.

On March 3, the Board released an update on strategy, goals and priorities. The company's strategy for entering into commercial agreements with industrial players has been and is clearly defined. It is based on four key priority activities:

  1. Drive an active business development agenda that proactively prepares for collaboration with existing and potential partners. This is partly to offer the opportunity to evaluate specific projects in combination with Ziccum's technology, and partly to understand the requirements placed on the technology before a decision on a license agreement can be made.
  2. Generate laboratory data that manifests and confirms the technology's capacity to dry different types of vaccines, so-called proof of concept.
  3. Develop the company's technology to adapt its functionality, capacity and quality to the licensees' required specifications.
  4. Develop conceptual plans for how Ziccum's drying technology can be adapted to the commercial scale and integrated into a commercial production environment.

With a new CEO, the Board's goal is to increase the pace of, above all, business development work – with the goal of entering into more industrial collaborations in order to evaluate LaminarPace and advance our existing collaborations into negotiations on commercial terms and license agreements.

On March 28, it was announced that Ann Gidner is appointed as new CFO for Ziccum, she takes office on May 9.

Significant events after the reporting period
The new CEO, Ann Gidner, has bought 15,000 shares in Ziccum. In addition, the Board members Andreas Pettersson also bought 20,000 shares and Kristian Kierkegaard 10,000 shares in the Company.

CEO Statement

This will be my final statement as acting CEO before our new CEO Ann Gidner assumes her new role on May 9. I am pleased that I will return to focusing fully on my CFO role having overseen a productive Quarter of renewed focus that I believe will serve as a basis for strong business development.

During the Quarter myself, together with Development Director Anna Lönn, an engaged Chairman and proactive Board member have worked intensively on reviewing the company’s business development and strategic focus. On March 3 we released an updated reappraisal of our strategic goals reaffirming the importance of licensing rights in our business model, and our commitment to generating further proof-of-concept data, and in particular mRNA / LNP data.

In the week leading up to this Q1 Report we shared with our investors additional details on our strategic and operational initiatives, and how they constitute a strong base for future growth. These focus areas are:

During 2022 – 2023 Ziccum will focus on three key vaccine platforms: the Viral Vector platform using Adenovirus, the subunit vaccine (adjuvanted) platform and the mRNA/LNP vaccine platform. mRNA/LNP is an area we value very high. The global trend and market dynamics in this specific field is also very strong. Read more HERE.

Strategic investments include a new cell lab that will enable in vitro studies of key biological properties and deliver specific advantages in the development of mRNA/LNP. We have also completed the investment and installation of the microfluidics system, ‘Ignite’ NanoAssemblr, that will enable us to generate our own mRNA/LNP materials at R&D scale. Read more HERE.

To underpin Ziccum’s new strategic focus, key technology development programs have been selected for the company’s flagship drying system (LaminarPace or LAPA) as it progresses towards eventual GMP manufacturing status. Some are ongoing, some have been recently completed. These technology development programs include for instance a new powder collector solution, introduction of nitrogen (N2) as drying gas, nebulizer and membrane development.

These key priority areas and a committed and engaged organization will lead the way in LaminarPace’s development towards commercial partnerships and eventual GMP industrial manufacturing. Read more HERE.

In conclusion – ‘renewed focus’ is the key term that I want to emphasis. I believe that with the new more focused strategies and targets developed in this Quarter, and with the imminent arrival of our reputable CEO Ann Gidner, we are now in a strong position to move decisively forwards towards creating new partnerships and value for ourselves, our clients and our investors.

Lund, April 28, 2022,
Frida Hjelmberg,
Ziccum AB